DGAP-News 530 0 Kommentare Announcement: 4SC to host conference call on 9 August 2012 to present Q2 2012 results

DGAP-News: 4SC AG / Key word(s): Miscellaneous/Miscellaneous
Announcement: 4SC to host conference call on 9 August 2012 to present
Q2 2012 results

02.08.2012 / 07:30

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR
INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, OR ANY JURISDICTION WHERE
TO DO SO WOULD CONSTITUTE A VIOLATION OF APPLICABLE LAWS OR REGULATIONS

Announcement

4SC to host conference call on 9 August 2012 to present Q2 2012 results

Planegg-Martinsried, Germany, 2 August 2012 - 4SC AG (Frankfurt, Prime
Standard: VSC), a discovery and development company of targeted small
molecule drugs for autoimmune diseases and cancer, will announce results of
the 4SC Group for the second quarter of 2012 and publish the Company´s half
year report 2012 on 9 August 2012. On this day the Management Board of 4SC
will host a conference call at 3pm CEST (9am EDT) to inform about the
consolidated financial statements in the reporting period and provide
further details on the Company´s latest developments.

Participants can access the conference call under the following telephone
numbers:

Date: 9 August 2012

Time: 3pm CEST (9am EDT)

Dial-in numbers:
+49-6103-485-3000 (Germany)
+44-207-153-2027 (UK)
+1-480-629-9870 (USA)
+49-6103-485-3000 (other countries)

Conference-ID: 4557873

Approximately two hours after the start of the live presentation, an audio
replay will be available at 4SC´s website www.4sc.com in the section
´Investors / Events & Presentations / Conference calls & Webcasts´.

Ends

About 4SC

The Group managed by 4SC AG (ISIN DE0005753818) discovers and develops
targeted, small-molecule drugs for treating diseases with high unmet
medical needs in various autoimmune and cancer indications. These drugs are
intended to provide innovative treatment options that are more tolerable
and efficacious than existing therapies, and provide a better quality of
life. The Company´s balanced pipeline comprises promising products that are
in various stages of clinical development. 4SC´s aim is to generate future
growth and enhance its enterprise value by entering into partnerships with
leading pharmaceutical companies. Founded in 1997, 4SC had 90 employees at
31 March 2012. 4SC AG has been listed on the Prime Standard of the
Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject
to risks and uncertainties, many of which are beyond our control. Actual
results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC
Jochen Orlowski, Corporate Communications & Investor Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66

MC Services
Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40

End of Corporate News

02.08.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP´s Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:    English
Company:     4SC AG
             Am Klopferspitz 19a
             82152 Martinsried
             Germany
Phone:       +49 (0)89 7007 63-0
Fax:         +49 (0)89 7007 63-29
E-mail:      public@4sc.com
Internet:    www.4sc.de
ISIN:        DE0005753818
WKN:         575381
Listed:      Regulierter Markt in Frankfurt (Prime Standard);
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart

End of News    DGAP News-Service

180013 02.08.2012